Efficiency of high-intensity therapy with rosuvastatin for secondary prevention of cardiovascular complications in patients with a very high risk
Open Access
- 21 January 2022
- journal article
- Published by Remedium, Ltd. in Atherothrombosis
- Vol. 11 (2), 56-75
- https://doi.org/10.21518/2307-1109-2021-11-2-56-75
Abstract
According to the latest international and Russian guidelines for the treatment of dyslipidemias, statins are defined as the main group of drugs that significantly reduce the level of low-density lipoprotein cholesterol (LDL-C) effectively prevent atherosclerotic cardiovascular diseases (CVD) and complications and can slow down the progression of atherosclerosis. The principle “the lower LDL-C, the better” is especially relevant in categories of patients with very high and extreme cardiovascular risk, and therefore, in order to achieve target LDL-C values (≤1.4 is optimal ≤1.0) in this category of patients, high-intensity lipid-lowering therapy should be used. Rosuvastatin remains the most effective statin. Its use makes possible to achieve target lipid values at the starting dose of treatment, enhances adherence to treatment, and also reduces the frequency of side effects associated with the use of high doses of other statins. In addition, the proven ability of rosuvastatin to reduce the volume of atherosclerotic plaque, by reducing the level of pro-inflammatory cytokines and C-reactive protein, normalizing endothelial function, antiplatelet action, that is, rosuvastatin, in addition to its powerful lipid-lowering effect, has anti-inflammatory and anti-ischemic effects. Also, rosuvastatin can be successfully used in the presence of comorbidities, including chronic kidney disease and chronic heart failure. Taking into consideration the urgency of the fight against the COVID-19 pandemic (coronavirus Disease 2019), which covered 220 countries, due to the lack of effective etiotropic drugs, the possibility of using statins, including rosuvastatin, for the treatment of comorbid patients with COVID-19, was evaluated.Keywords
This publication has 41 references indexed in Scilit:
- Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular DiseaseClinical Medicine Insights: Cardiology, 2012
- Effect of Two Intensive Statin Regimens on Progression of Coronary DiseaseThe New England Journal of Medicine, 2011
- METEOR Trial Reports on the Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals with Subclinical AtherosclerosisThe Physician and Sportsmedicine, 2010
- Rosuvastatin and Cardiovascular Events in Patients Undergoing HemodialysisThe New England Journal of Medicine, 2009
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Secondary Prevention of Coronary Heart Disease in Elderly Patients Following Myocardial InfarctionDrugs & Aging, 2008
- Rosuvastatin in Older Patients with Systolic Heart FailureThe New England Journal of Medicine, 2007
- Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy: A PROVE IT-TIMI 22 SubstudyJournal of Invasive Cardiology, 2005
- Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes: Results From the PROVE IT-TIMI 22 TrialJournal of Invasive Cardiology, 2005
- Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trialCurrent Medical Research and Opinion, 2003